SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agenus (AGEN)
AGEN 3.260-6.9%3:40 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Area51 who wrote (30)12/16/2015 1:02:34 PM
From: Kirk ©   of 146
 
Are you still posting here on SI?

Nice jump today on this news:
Jefferies Starts Agenus Inc. (AGEN) at Buy; Sees 100% Upside
December 16, 2015 7:54 AM EST

Jefferies initiates coverage on Agenus Inc. (NASDAQ: AGEN) with a Buy rating and a price target of $8.00.

Analyst Biren Amin commented, "Agenus is developing a comprehensive Immuno-Oncology (IO) platform consisting of multiple checkpoints both fully owned and through partnerships and could be a leader in cancer vaccine development through the deployment of its QS-21 adjuvant which could increase the efficacy of cancer vaccines. AGEN is also partnered with Merck and Incyte across 9 novel IO programs totaling >$450M in milestones. Therefore, AGEN's $130M EV offers significant upside, in our view."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext